Bristol-Myers Squibb | BMY - Assets


Bristol-Myers Squibb reported $88.77B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Abbott USD 108.25B 968M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Amgen USD 96.05B 409M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Drreddys Laboratories INR 574.48B 4.86B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Medtronic USD 93.31B 278M Jun/2026
Merck USD 132.77B 2.97B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Phibro Animal Health USD 1.51B 13.48M Sep/2026
Prestige Brands USD 4.72B 153.09M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 130.29B 1.23B Sep/2026
Sanofi EUR 129.06B 1.04B Jun/2026
United Therapeutics USD 7.03B 186M Sep/2026
Zoetis USD 15.09B 11M Sep/2026